SLC5A2 and heart failure: Protection against macrovascular outcomes has been found to be even greater with use of newer antidiabetic agents such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA), particularly for heart failure [9–12].